Heparin Pharmacokinetics and Clinical Implications

Unfractionated Heparin (UFH) Pharmacokinetics

UFH is cleared through a combination of rapid saturable mechanisms and slower first-order mechanisms, primarily renal clearance, with a half-life of approximately 1.5 hours when administered intravenously 1
The anticoagulant effect of UFH is immediate when given intravenously but delayed by 1-2 hours when administered subcutaneously 1
UFH's clearance is non-linear at therapeutic doses, with both intensity and duration of effect rising disproportionately with dose 1

LMWHs have a longer elimination half-life of 3-6 hours after subcutaneous injection 2
The half-life of LMWH is dose-independent, unlike UFH 2
Anti-Xa levels peak 3-5 hours after subcutaneous administration of LMWH 2
LMWHs have higher bioavailability (approximately 90%) compared to UFH when administered subcutaneously 2
LMWHs are predominantly cleared by the kidneys, which may prolong their biological half-life in patients with renal failure 2

For LMWH, routine coagulation monitoring is generally not necessary except in specific populations (obese patients, renal insufficiency, pregnancy) 2
When treating venous thromboembolism, a 5-day course of heparin has been shown to be as effective as a 10-day course 3

Platelet counts should be monitored periodically during heparin therapy due to the risk of heparin-induced thrombocytopenia (HIT), which typically appears after 4-14 days of therapy 4
Significant thrombocytopenia occurs in 1-5% of patients receiving heparin, while autoimmune HIT with thrombosis is a rare but dangerous complication (less than 0.2% incidence) 4

Unfractionated heparin has poor bioavailability when administered subcutaneously compared to low molecular weight heparins, as noted by the American Heart Association 5, 6

The longer half-life of enoxaparin allows for once or twice daily dosing regimens, while unfractionated heparin often requires continuous infusion or more frequent administration, according to the American College of Cardiology 6, 7
Enoxaparin provides more consistent anticoagulation with less need for laboratory monitoring due to its more predictable pharmacokinetics, as stated by the American Heart Association 8

Low molecular weight heparins like enoxaparin are not interchangeable due to differences in their preparation methods and resulting pharmacokinetic properties, as highlighted by the American College of Chest Physicians 5, 6
The longer half-life of enoxaparin contributes to its superior pharmacokinetic profile, which is considered its most clinically important advantage over unfractionated heparin, as noted by the European Society of Cardiology 5, 6

The European Society of Cardiology recommends target ranges of 0.6-1.0 IU/mL for twice-daily dosing and 1.0-2.0 IU/mL for once-daily dosing of low molecular weight heparins (LMWH), while fondaparinux therapeutic levels should be 1.20-1.26 mg/L 9
Anti-Xa monitoring is not routinely required for patients on standard doses of LMWH but should be considered in specific populations, including patients with severe renal impairment 10, pregnant women 9, and patients on intermediate or therapeutic dosing regimens [10] [9]
For fondaparinux, routine monitoring is generally not recommended but may be useful in certain clinical situations, with peak steady-state plasma concentration reached approximately 3 hours post-dose 11

For LMWH, samples should be collected 4 hours after subcutaneous administration, when anti-Xa levels peak [9] [10]
Anti-Xa assays must use the appropriate calibrator for the specific anticoagulant being monitored, with LMWH-specific calibrators for LMWH monitoring 12 and fondaparinux-specific calibrators for fondaparinux monitoring 11

Recent use of oral factor Xa inhibitors can interfere with anti-Xa assays, leading to falsely elevated results, with interference persisting for up to 3 days after discontinuation [13] [12]
High levels of fibrinogen or factor VIII can affect heparin activity and monitoring 10
Do not use activated partial thromboplastin time (aPTT) for monitoring LMWH or fondaparinux, as it is insensitive to their activity 10
Renal impairment can significantly prolong the half-life of both LMWH and fondaparinux, potentially leading to accumulation 11

The American College of Obstetricians and Gynecologists recommends a standard prophylactic dose of 40 mg subcutaneously once daily, taking advantage of the prolonged duration of action of enoxaparin, which enables once or twice daily dosing regimens without the need for continuous infusion 14
Enoxaparin maintains its favorable pharmacokinetic profile in pregnancy, with a longer half-life making it the preferred agent, according to the American College of Obstetricians and Gynecologists 14